By: Parvathy Rajagopal  Oct. 09, 2020

Dexur analyzed the Medicare Claims data to evaluate Value-Based Purchasing(VBP) payment adjustment and found that Renown Regional Medical Center in Reno, Nevada, had a projected negative financial impact of $178,000 in 2020. During FY 2020, the VBP adjustment factor was 0.99 which reflected a VBP payment adjustment percentage of -0.16.

By: Barsha Nandy  Oct. 06, 2020

Dexur analyzed Medicare Claims data to evaluate Value-Based Purchasing (VBP) payment adjustment and found that Ocala Regional Medical Center had the highest projected negative financial impact of $1.2m. For FY 2020, their VBP adjustment factor was 0.986, which translated into a payment adjustment percentage of -1.4. The adjustment amount has gradually increased, almost by 30%, since an adjustment of $830,288 was made in 2018 against Ocala’s favor.

Heron Therapeutics, Inc., a commercial-stage biotechnology company utilizes Dexur’s App suite to increase velocity in commercial operations.

“Dexur’s App Suite and implementation services is a key strategic partner to help scale ClearFlow. The breadth and depth of Dexur’s offering across data, sales analytics, and marketing automation has made Dexur a critical element in articulating ClearFlow’s value to healthcare providers” said Paul Molloy, CEO of ClearFlow.

By: Barsha Nandy  Oct. 01, 2020

Dexur analyzed Medicare Claims data to evaluate Bundled Payments for Care Improvement Advanced (BPCI-A) episode costs for Inpatient Hip and Knee Replacement Surgery in Texas and found that Baylor Hospitals in Frisco, Sherman, Fort Worth & Trophy Club performed the best and reduced total costs by 10-20%. The biggest cause of these changes was a reduction in post anchor stay costs of Rehospitalizations, Skilled Nursing Homes & Home Health. Providence (Waco), Medical City (Plano, Arlington), Texoma (Denniston) Hospital saw little change or increased costs under the same program.

AltaThera Pharmaceuticals, a hospital specialty pharmaceutical company focused on commercializing innovative drugs aimed at improving outcomes and reducing hospital costs, chose Dexur’s App Suite to help scale the operations of the company. AltaThera recently received approval from the FDA for new indications of Sotalol IV, to help hospitals manage patients with Afib.

By: Parvathy Rajagopal  Sep. 23, 2020

Dexur’s analysis of Medicare claims of hospitals within a 10-mile radius of Slidell, LA, showed that Ochsner Medical Center - NorthShore and Slidell Memorial Hospital had the best value outcomes over a 90-day episode for Sepsis. Dexur’s value analysis tracks a patient’s episode of care from the date of admission for 90 days, including the index hospitalizations, rehospitalization, home health, nursing home, and ED costs. The total cost of care data helps patients make appropriate choices and helps local ACOs make appropriate referrals choices. The analysis was risk-adjusted, for alive and non-hospice patients and was done at the DRG level, specifically DRG 871: Septicemia or Severe Sepsis without MV >96 Hours with Major Complication or Comorbidity, to adjust for complications and comorbidities.

By: Parvathy Rajagopal  Sep. 22, 2020

Dexur’s analysis of medicare claims of hospitals within a 10-mile radius of Wilkes-Barre, Pennsylvania, showed that Wilkes-Barre General Hospital and Geisinger Wyoming Valley Medical Center had the best value outcomes over a 90 day episode for Hip & Knee replacement. Dexur’s value analysis tracks a patient’s episode of care from the date of admission for 90 days and includes the index hospitalizations, rehospitalization, home health, nursing home, and ED costs. Total cost of care data helps patients make appropriate choices and helps local ACOs make appropriate referral choices. The analysis was risk-adjusted, for alive and non-hospice patients and was done at the DRG level, specifically DRG 470: Major Joint Replacement or Reattachment of Lower Extremity without Major Complication or Comorbidity (MCC), to adjust for complications and comorbidities.

By: Sruthy Iype  Sep. 21, 2020

Dexur’s analysis of Medicare claims data showed that Xolair’s patient share for asthma was 1.6 times more than Nucala and twice that of Fasenra in 2019. The study was based on the J code usage of biologic therapies - Xolair, Nucala, Fasenra, and Cinqair - for asthma among Medicare patients who received treatments in hospital outpatient settings between Jan and Dec 2019. The analysis also looks at the average claims per patient data, which is a proxy for the number of injections / IV infusions / doses administered to a patient.

By: Parvathy Rajagopal  Sep. 21, 2020

Dexur’s analysis of medicare claims of hospitals within a 10-mile radius of Jonesboro, Arkansas, showed that NEA Baptist Memorial Hospital and St. Bernards Medical Center had the best value outcomes over a 90 day episode for Hip & Knee replacement. Dexur’s value analysis tracks a patient’s episode of care from the date of admission for 90 days and includes the index hospitalizations, rehospitalization, home health, nursing home, and ED costs. Total cost of care data helps patients make appropriate choices and helps local ACOs like SBMACO, LLC., make appropriate referral choices. The analysis was risk-adjusted, for alive and non-hospice patients and was done at the DRG level, specifically DRG 470: Major Joint Replacement or Reattachment of Lower Extremity without Major Complication or Comorbidity (MCC), to adjust for complications and comorbidities.